Clinical Trials Logo

Clinical Trial Summary

Preterm newborns survival rates are improved, but long-term disabilities are still common. Major destructive focal lesions became less common, the most predominant lesion at present is diffuse white matter (WM damage). Melatonin (ME) serves as a neuroprotectant cerebral ischemia through its potent anti-oxidant/-inflammatory effect. Preclinical studies demonstrated that protects the developing brain by preventing abnormal myelination and inflammatory glial reaction. Clinical studies demonstrated ME ability in reducing brain damage after neonatal Hypoxic Ischemic Encephalopathy (HIE) or preventing neonatal impairments due to antenatal/ post-natal injuries: preeclampsia, IntraUterineGrowthRestriction (IUGR), ventilation, Bronchopulmonary Dysplasia (BPD). ME has a good safety profile with no known adverse effects. This study aims to highlight that ME can prevent brain impairment due to premature birth. ME will be administered orally (3 mg/kg/die for 15 days to neonates born before 29+6 week gestation, in a prospective double blind, randomized vs placebo study, 2 parallel arms. ME and malondialdehyde (MDA), a lipid peroxidation product) levels before and at the end of treatment will be measured . Other outcomes: Cerebral ultrasounds (cUS); cerebral magnetic resonance imaging (cMRI), " Fagan test " eye tracking, ophthalmological, auditory, neurological/cognitive child assessments. Monitoring parental distress, which can influence the neurodevelopmental outcome in preterms.


Clinical Trial Description

About 552.000 infants are born in Italy each year, 1% of them with gestational age under 30 weeks. Survival rates are improved, but long-term disabilities are still common. Major destructive focal lesions became less common, the most predominant lesion at present is diffuse white matter (WM damage). The prevention of neurodevelopmental impairment is a major public health challenge and efforts are needed to test neuroprotective strategies. Melatonin (ME) serves as a neuroprotectant cerebral ischemia through its potent anti-oxidant/-inflammatory effect. Preclinical studies demonstrated that protects the developing brain by preventing abnormal myelination and inflammatory glial reaction. Clinical studies demonstrated ME ability in reducing brain damage after neonatal Hypoxic Ischemic Encephalopathy (HIE) or preventing neonatal impairments due to antenatal/ post-natal injuries: preeclampsia, IntraUterineGrowthRestriction (IUGR), ventilation, Bronchopulmonary Dysplasia (BPD). Ongoing studies are testing in premature neonates and pregnant women its neuroprotective properties. ME has a good safety profile with no known adverse effects. This study aims to highlight that ME can prevent brain impairment due to premature birth. ME will be administered orally (3 mg/kg/die for 15 days within 96 hours from birth) to neonates born before 29+6 week gestation age (GA), in a prospective double blind, randomized vs placebo study, 2 parallel arms (30 preterm infants each). ME and malondialdehyde (MDA, a lipid peroxidation product) levels will be measured before and at the end of treatment. At birth, within 40 weeks of neonatal age, at 4-6 and at 24 months of age the following examinations are performed: Cerebral ultrasounds (cUS); cerebral magnetic resonance imaging (cMRI), during natural sleep (i.e. adopting sleep deprivation and/or feeding protocols); "Fagan test"eye tracking, ophthalmological, auditory brain stem evoked response (ABR), neurological/cognitive child assessments. Monitoring parental distress, which can influence the neurodevelopmental outcome in preterms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04235673
Study type Interventional
Source IRCCS Policlinico S. Matteo
Contact
Status Completed
Phase N/A
Start date May 25, 2020
Completion date October 11, 2022

See also
  Status Clinical Trial Phase
Completed NCT04665453 - Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children N/A
Suspended NCT05107947 - Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm N/A
Completed NCT02936674 - Color-dependent Melatonin Suppression N/A
Recruiting NCT06076668 - Dexmedetomidine Infusion Versus Oral Melatonin for Prevention of Intensive Care Delirium N/A
Enrolling by invitation NCT04230707 - Endogenous Melatonin Levels on Anxiety in Living Liver Donors
Terminated NCT03725267 - Melatonin for Renal Protection in Patients Receiving Polymyxin B Phase 2
Completed NCT02642640 - Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1 N/A
Completed NCT03519750 - Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Melatonin in Healthy Female Volunteers Phase 1
Enrolling by invitation NCT03107702 - Melatonin Level and Postoperative Analgesia Consumption in Bariatric Surgery Patients. N/A
Completed NCT03478306 - Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm Phase 3
Recruiting NCT04278456 - Postpartum Depression
Recruiting NCT03966950 - Use of Melatonin for Preventing POCD in Transurethral Prostate Resection Under Spinal Anesthesia N/A
Completed NCT04392063 - Melatonin for Cerebral Palsy Children's Sleep and Health N/A
Completed NCT05309681 - Salivary Melatonin Levels and Sleep Quality in Patients With Burning Mouth Syndrome
Completed NCT05492812 - Sedation and Nursing Management in EEG Recording in Children N/A
Completed NCT03230630 - Plasma Melatonin AND Mortality After Acute Myocardial Infarction N/A
Completed NCT05870358 - Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis Phase 4
Completed NCT03464084 - Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2 N/A
Recruiting NCT06237556 - Melatonin on Anxiety and Sleep Quality in Adults Undergoing Coronary Artery Bypass Graft Surgery N/A
Recruiting NCT03013790 - Melatonin Use in the Intensive Care Elderly Population Phase 4